8-Aug-2025 5:30 AM CST - Business Wire Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025 $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received gross proceeds of $4 million from public offering in May 2025 "The Revelation team con
8-May-2025 3:15 PM CST - Business Wire Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025 $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in
13-Mar-2025 5:00 AM CST - Business Wire Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelations Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA. The fireside chat will be webcast live here and available on our Investors section of
6-Mar-2025 3:15 PM CST - Business Wire Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FD
8-Nov-2024 3:15 PM CST - Business Wire Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Recei
8-Aug-2025 5:30 AM CST - Business Wire Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025 $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received gross proceeds of $4 million from public offering in May 2025 "The Revelation team con
8-May-2025 3:15 PM CST - Business Wire Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025 $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in
13-Mar-2025 5:00 AM CST - Business Wire Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelations Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA. The fireside chat will be webcast live here and available on our Investors section of
6-Mar-2025 3:15 PM CST - Business Wire Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FD
8-Nov-2024 3:15 PM CST - Business Wire Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Recei
